Organogenesis (ORGO) Revenue & Revenue Breakdown
Organogenesis Revenue Highlights
Latest Revenue (Y)
$433.14M
Latest Revenue (Q)
$130.23M
Main Segment (Y)
Advanced Wound care
Organogenesis Revenue by Period
Organogenesis Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $433.14M | -3.94% |
| 2022-12-31 | $450.89M | -3.67% |
| 2021-12-31 | $468.06M | 38.36% |
| 2020-12-31 | $338.30M | 29.63% |
| 2019-12-31 | $260.98M | 34.91% |
| 2018-12-31 | $193.45M | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | - |
Organogenesis generated $433.14M in revenue during NA 2023, up -3.94% compared to the previous quarter, and up 223.90% compared to the same period a year ago.
Organogenesis Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $130.23M | 18.42% |
| 2024-03-31 | $109.98M | 10.36% |
| 2023-12-31 | $99.65M | -8.18% |
| 2023-09-30 | $108.53M | -7.49% |
| 2023-06-30 | $117.32M | 8.99% |
| 2023-03-31 | $107.64M | -6.82% |
| 2022-12-31 | $115.52M | -1.15% |
| 2022-09-30 | $116.86M | -3.74% |
| 2022-06-30 | $121.40M | 23.73% |
| 2022-03-31 | $98.12M | -23.68% |
| 2021-12-31 | $128.56M | 13.02% |
| 2021-09-30 | $113.75M | -7.67% |
| 2021-06-30 | $123.20M | 20.13% |
| 2021-03-31 | $102.55M | -3.98% |
| 2020-12-31 | $106.81M | 5.96% |
| 2020-09-30 | $100.80M | 46.17% |
| 2020-06-30 | $68.96M | 11.71% |
| 2020-03-31 | $61.73M | -17.30% |
| 2019-12-31 | $74.64M | 16.15% |
| 2019-09-30 | $64.27M | -1.05% |
| 2019-06-30 | $64.95M | 13.70% |
| 2019-03-31 | $57.12M | -10.18% |
| 2018-12-31 | $63.60M | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | -100.00% |
| 2017-12-31 | $6.59M | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | -100.00% |
| 2016-12-31 | $61.08K | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | - |
Organogenesis generated $130.23M in revenue during Q2 2024, up 18.42% compared to the previous quarter, and up 120.99% compared to the same period a year ago.
Organogenesis Revenue Breakdown
Organogenesis Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Surgical and Sports Medicine | $27.63M | $28.66M | $37.22M | $43.67M | $40.24M |
| Advanced Wound care | $405.51M | $422.23M | $430.84M | $294.62M | $220.74M |
Organogenesis's latest annual revenue breakdown by segment (product or service), as of Dec 23: Advanced Wound care (93.62%), and Surgical and Sports Medicine (6.38%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Surgical and Sports Medicine | $6.11M | $6.49M | $7.17M | $7.24M | $6.72M | $6.68M | $7.34M | $7.61M | $7.17M | $7.20M | $6.41M | $11.76M | $11.84M | $13.19M | $10.81M | $9.23M | $10.44M | $11.27M | $9.96M | $9.74M |
| Advanced Wound care | $103.86M | $93.17M | $101.36M | $110.08M | $100.92M | $108.84M | $109.51M | $113.79M | $90.95M | $121.35M | $107.34M | $111.44M | $90.71M | $93.61M | $89.99M | $59.73M | $51.29M | $63.38M | $54.31M | $55.21M |
Organogenesis's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Advanced Wound care (94.44%), and Surgical and Sports Medicine (5.56%).
Organogenesis Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| PTPI | Petros Pharmaceuticals | $5.82B | $1.39M |
| NBIX | Neurocrine Biosciences | $1.89B | $590.20M |
| ALKS | Alkermes | $1.66B | $399.13M |
| COLL | Collegium Pharmaceutical | $566.77M | $144.92M |
| ITCI | Intra-Cellular Therapies | $462.18M | $144.87M |
| ORGO | Organogenesis | $433.14M | $130.23M |
| DVAX | Dynavax | $232.28M | $73.80M |
| DCPH | Deciphera Pharmaceuticals | $163.36M | $45.00M |
| LFCR | Lifecore Biomedical | $128.26M | $35.70M |
| ALIM | Alimera Sciences | $80.75M | $23.01M |
| TKNO | Alpha Teknova | $36.68M | $9.61M |
| GHSI | Guardion Health Sciences | $12.25M | $36.35K |
| RDHL | RedHill Biopharma | $6.51M | $1.80M |
| ADMP | Adamis Pharmaceuticals | $4.76M | $9.06M |
| LSDI | Lucy Scientific Discovery | $7.05K | $9.68K |
| SHPH | Shuttle Pharmaceuticals | - | - |
ORGO Revenue FAQ
What is Organogenesis’s yearly revenue?
Organogenesis's yearly revenue for 2023 was $433.14M, representing a decrease of -3.94% compared to 2022. The company's yearly revenue for 2022 was $450.89M, representing a decrease of -3.67% compared to 2021. ORGO's yearly revenue for 2021 was $468.06M, representing an increase of 38.36% compared to 2020.
What is Organogenesis’s quarterly revenue?
Organogenesis's quarterly revenue for Q2 2024 was $130.23M, a 18.42% increase from the previous quarter (Q1 2024), and a 11.01% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $109.98M, a 10.36% increase from the previous quarter (Q4 2023), and a 2.17% increase year-over-year (Q1 2023). ORGO's quarterly revenue for Q4 2023 was $99.65M, a -8.18% decrease from the previous quarter (Q3 2023), and a -13.73% decrease year-over-year (Q4 2022).
What is Organogenesis’s revenue growth rate?
Organogenesis's revenue growth rate for the last 3 years (2021-2023) was -7.46%, and for the last 5 years (2019-2023) was 65.97%.
What are Organogenesis’s revenue streams?
Organogenesis's revenue streams in c 23 are Surgical and Sports Medicine, and Advanced Wound care. Surgical and Sports Medicine generated $27.63M in revenue, accounting 6.38% of the company's total revenue, down -3.61% year-over-year. Advanced Wound care generated $405.51M in revenue, accounting 93.62% of the company's total revenue, down -3.96% year-over-year.
What is Organogenesis’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Organogenesis was Advanced Wound care. This segment made a revenue of $405.51M, representing 93.62% of the company's total revenue.